项目由麻省理工學院Robert S. Langer 博士和Shuguang Zhang博士為技術負責人，
利用創新的“QTY碼”修飾蛋白作為新型治療靶點
2019年5月21日新澤西州Freehold——國際領先的細胞生物技術公司Avalon Globocare (NASDAQ：AVCO) 今天宣佈，公司已與麻省理工學院（MIT）簽署了一項贊助研究和授權協定，將利用人工智慧（AI） 增強蛋白設計“QTY 碼”為細胞治療生成新型治療靶點。“QTY 碼”這一突破性技術大幅提升了設計肽和蛋白質的溶解度，從而擴大了針對癌症和其他疾病的選定治療靶點的範圍。Avalon將與麻省理工學院Robert S. Langer 博士和Shuguang Zhang博士共同啟動研究和研發，针对細胞因子釋放綜合征（Cytokine Release Syndrome）、T細胞白血病（T-cell leukemia）的下一代療法，以及為細胞免疫治療重新設計免疫細胞的新方法。
Avalon GloboCare的CEO兼總裁David Jin博士表示：“我們非常榮幸能與麻省理工學院合作，在 Langer 博士和 Zhang 博士的領導下，研發和應用這種前沿的AI增強蛋白設計QTY碼技術。這將極大地豐富我們上游的研發創新，並與我們最先進的生產製備以及下游的針對細胞治療臨床患者的管理形成無縫整合。”
Avalon GloboCare Corp.（NASDAQ: AVCO）是一家國際領先的細胞技術開發公司，致力於開發和轉化具有創新性、變革性的外泌體和細胞治療技術。 Avalon也提供戰略諮詢和技術合作服務，以協助促進其客戶在技術開發領域的發展，提高其在本國和全球醫療市場的競爭力。通過子公司GenExosome Technologies Inc.和Avactis Biosciences Inc.，Avalon在基於外泌體的診斷(“液體活檢”) 、細胞免疫治療(包括CAR-T/CAR-NK) 和再生醫學領域建立了領先地位。
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
[email protected]
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
[email protected]
